Healthcare / Medical Instruments & SuppliesTaiwan
$38.65
-0.15 (-0.39%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 23% · confianza 25%
FCF escenarios
weak_data · normalized FCF $207.6M · quality 80.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
47/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$3.5B
P/E
13.2x
↓EV/EBITDA
8.9x
↓ROE
17.3%
↑Gross Margin
69.5%
↑Debt/Equity
0.07
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+10.3%
FCF CAGR
-6.5%
FCF margin
25.6%
FCF / Net income
0.78x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $811.6M · net income $265.3M · FCF $207.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $811.6M | $811.6M | $680.7M | $622.1M | $604.4M |
| Net Income | $265.3M | $265.3M | $190.2M | $165.8M | $139.4M |
| EBITDA | $337.1M | $337.1M | $252.6M | $177.7M | $195.4M |
| EPS | — | — | 2.12 | 1.85 | 1.56 |
| Gross Margin | 69.5% | 69.5% | 71.0% | 68.2% | 61.9% |
| Operating Margin | 31.3% | 31.3% | 28.6% | 24.1% | 22.1% |
| Net Margin | 32.7% | 32.7% | 27.9% | 26.7% | 23.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.07 | 0.07 | — | 0.00 | — |
| Current Ratio | 3.32 | 3.32 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $207.6M | $207.6M | $266.5M | $148.8M | $253.9M |
| Returns | |||||
| ROE | 17.3% | 17.3% | 13.8% | 12.2% | 10.8% |
| Valuation | |||||
| P/E | 13.19 | 13.19 | 23.63 | 25.81 | 28.14 |
| EV/EBITDA | 8.87 | 8.87 | 15.26 | 21.62 | 16.04 |
| P/B | 2.25 | 2.25 | 3.27 | 3.14 | 3.03 |
| Growth & Yield | |||||
| Revenue Growth | 19.2% | 19.2% | 9.4% | 2.9% | — |
| EPS Growth | — | — | 14.6% | 18.6% | — |
| Dividend Yield | 2.1% | 2.1% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-8.5%
Start / end P/E
n/dx → n/dx
EPS bridge
2.12 → n/d
Residual
-10.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.